2026-10-14T18:13:58Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33943241 2026-09-19T17:50:32Z category_7 category_16 category_19 category_21 category_46 category_734 category_64 category_106 portal_87 item_type_3 month_year_09_2026

Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis Ahmed Farid Gadelmawla (19236447) Ahmed A. Abo Elnaga (20718759) Abdullah Faisal Albukhari (25076549) Raseel B. Almutairi (25076552) Basmah Alamri (25076555) Sami Mohammed Alhuways (25076558) Fatemah Althaher (25076561) Flwah Aloufi (25076564) Abdullah Mohammed A. Alotaibi (25076567) Abdullah Alali (25076570) Ali Almatri (25076573) Hamad Althawadi (25076576) Abdullah Altamimi (18594955) Medicine Physiology Pharmacology Biotechnology Immunology Biological Sciences not elsewhere classified Cancer Science Policy Anlotinib combination therapy immune checkpoint inhibitors sarcoma soft-tissue sarcoma Advanced or metastatic soft-tissue sarcoma (STS) responds poorly to standard chemotherapy. Anlotinib has shown activity across multiple treatment lines, including first-line and maintenance therapies, though monotherapy benefit remains limited. This study aimed to quantify the efficacy of anlotinib plus PD-1/PD-L1 inhibitors in advanced or metastatic soft-tissue sarcoma (STS). We conducted a PRISMA-adherent systematic review of PubMed, Scopus, and Web of Science from inception to October 2025. Studies enrolling adults with advanced or metastatic STS treated with anlotinib plus a PD-1/PD-L1 inhibitor were eligible. Pooled analyses were performed in R using the meta package under inverse-variance random-effects models. Seven studies were included. The pooled objective response rate was 37.3% (95% CI, 17.0–60.4), and the pooled disease control rate was 77.2% (95% CI, 71.7–82.4). Complete and partial responses occurred in 4.3% (95% CI, 1.4–8.8) and 29.9% (95% CI, 13.4–49.6), respectively, with stable disease in 50.6% (95% CI, 39.5–61.8). The pooled 6-month progression-free survival (PFS-6) rate was 61.1% (95% CI, 22.1–93.1). Among advanced or metastatic STS cohorts, combination therapy with anlotinib and PD-1/PD-L1 inhibitors showed encouraging objective responses and disease control. These outcomes appeared numerically higher than those historically reported with monotherapy, although the evidence remains limited by small sample sizes, non-randomized designs, and histologic heterogeneity. PROSPERO (URL: <a target="_blank" href="https://www.crd.york.ac.uk/PROSPERO/view/CRD420251232427">https://www.crd.york.ac.uk/PROSPERO/view/CRD420251232427</a>), identifier is CRD420251232427. Soft-tissue sarcoma is a rare type of cancer that starts in muscles, fat, blood vessels, or other soft tissues. This cancer is difficult to treat when it has spread or cannot be removed by surgery. Many patients do not respond well to standard chemotherapy, so new treatment options are needed. This study looked at a treatment that combines anlotinib with immune checkpoint inhibitors. Anlotinib is a drug that blocks the signals tumors use to form new blood vessels. Immune checkpoint inhibitors help the body’s immune system recognize and attack cancer cells. We reviewed 7 studies that included patients with advanced or metastatic soft-tissue sarcoma who received this treatment combination. When we combined the results, we found encouraging signs of benefit. About 1 in 3 patients had their tumors shrink. In many other patients, the cancer stopped growing for a period of time. Many patients were still free from disease progression at 6 months. These findings suggest that this treatment may be helpful for some patients with advanced soft-tissue sarcoma. However, the available evidence remains limited. The included studies were small, and none of them were randomized clinical trials. The patients also had different types of sarcoma and different prior treatments. Larger and better-designed studies are needed to confirm how effective this treatment is and to identify which patients are most likely to benefit from it. 2026-09-19T17:50:32Z Dataset Dataset 10.6084/m9.figshare.33943241.v1 https://figshare.com/articles/dataset/Efficacy_of_anlotinib_plus_immune_checkpoint_inhibitors_in_soft-tissue_sarcoma_systematic_review_and_meta-analysis/33943241 CC BY 4.0